BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. SN Compr Clin Med 2021;:1-5. [PMID: 33644693 DOI: 10.1007/s42399-021-00824-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Saifi S, Ravi V, Sharma S, Swaminathan A, Chauhan NS, Pandey R. SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength? Genomics 2022;114:110466. [PMID: 36041637 DOI: 10.1016/j.ygeno.2022.110466] [Reference Citation Analysis]
2 Sen S, Singh B, Biswas G. Corticosteroids: A Boon or Bane for COVID-19 Patients? Steroids 2022;:109102. [PMID: 36029810 DOI: 10.1016/j.steroids.2022.109102] [Reference Citation Analysis]
3 Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland KK, Charoenpong L, Rattanasompattikul M, Mahasirimongkol S, Wichukchinda N, Chokephaibulkit K. Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study. Emerg Microbes Infect 2022;:1-47. [PMID: 35997325 DOI: 10.1080/22221751.2022.2117092] [Reference Citation Analysis]
4 Mavlankar A, Ansari A, Sharma M, Dwivedi P, Singh P. Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study. F1000Res 2022;11:400. [DOI: 10.12688/f1000research.109586.1] [Reference Citation Analysis]
5 Sanghavi D, Bansal P, Kaur IP, Mughal MS, Keshavamurthy C, Cusick A, Schram J, Yarrarapu SNS, Giri AR, Kaur N, Moreno Franco P, Abril A, Aslam F. Impact of colchicine on mortality and morbidity in COVID-19: a systematic review. Ann Med 2022;54:775-89. [PMID: 35258357 DOI: 10.1080/07853890.2021.1993327] [Reference Citation Analysis]
6 Prathapan P. A determination of pan-pathogen antimicrobials? Medicine in Drug Discovery 2022. [DOI: 10.1016/j.medidd.2022.100120] [Reference Citation Analysis]
7 Surve RM, Mishra RK, Malla SR, Kamath S, Chakrabarti DR, Kulanthaivelu K, Musunuru M. Clinical Characteristics and Outcomes of Critically Ill Neurological Patients with COVID-19 Infection in Neuro-intensive Care Unit: A Retrospective Study. Indian J Crit Care Med 2021;25:1126-32. [PMID: 34916744 DOI: 10.5005/jp-journals-10071-23989] [Reference Citation Analysis]
8 Harigua-Souiai E, Heinhane MM, Abdelkrim YZ, Souiai O, Abdeljaoued-Tej I, Guizani I. Deep Learning Algorithms Achieved Satisfactory Predictions When Trained on a Novel Collection of Anticoronavirus Molecules. Front Genet 2021;12:744170. [PMID: 34912370 DOI: 10.3389/fgene.2021.744170] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Kelleni MT. NSAIDs and Kelleni's protocol as potential early COVID-19 treatment game changer: could it be the final countdown? Inflammopharmacology 2021. [PMID: 34822026 DOI: 10.1007/s10787-021-00896-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Chaisuwan W, Phimolsiripol Y, Chaiyaso T, Techapun C, Leksawasdi N, Jantanasakulwong K, Rachtanapun P, Wangtueai S, Sommano SR, You S, Regenstein JM, Barba FJ, Seesuriyachan P. The Antiviral Activity of Bacterial, Fungal, and Algal Polysaccharides as Bioactive Ingredients: Potential Uses for Enhancing Immune Systems and Preventing Viruses. Front Nutr 2021;8:772033. [PMID: 34805253 DOI: 10.3389/fnut.2021.772033] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
11 Kumar S, Çalışkan DM, Janowski J, Faist A, Conrad BCG, Lange J, Ludwig S, Brunotte L. Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. Front Immunol 2021;12:752227. [PMID: 34659259 DOI: 10.3389/fimmu.2021.752227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ferreto LED, Bortoloti DS, Fortes PCN, Follador F, Arruda G, Ximenez JP, Wendt GW. Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis. Sao Paulo Med J 2021;139:657-61. [PMID: 34644768 DOI: 10.1590/1516-3180.2021.0120.R1.30062021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Carta A, Conversano C. Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. BMC Health Serv Res 2021;21:986. [PMID: 34537034 DOI: 10.1186/s12913-021-06998-w] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Kelleni MT. NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. Expert Rev Anti Infect Ther 2021;:1-5. [PMID: 34088250 DOI: 10.1080/14787210.2021.1939683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]